Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Journal of the Peripheral Nervous System · 2025
DOI: 10.1111/jns.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2025. Verfasst von Shiwen Koay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCLH, London, UK. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulins, Intravenous, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCLH Biomedical Research Centre.
Abstract (Originalsprache)
Background and Aims Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common chronic autoimmune neuropathy worldwide. A significant proportion of CIDP patients enter spontaneous or medication‐related remission, remaining stable without immunotherapy. Overtreatment of CIDP has clinical and financial implications. We examined performance of IVIg cessation trials in our CIDP cohort and report safety and cost analysis outcomes.
Methods
In individuals with CIDP on maintenance IVIg treatment, a cessation trial was proposed in clinically stable patients with a static IVIg regimen over a 12‐month period. We explored the proportion who were stable off treatment for 12 or more months and the time to recovery in those who declined and were re‐treated. We examined cost implications of this approach.
Results
45/125 individuals met criteria for clinical stability, with median age 58 years, I‐RODS 37/48, MRC‐SS 69/70 and annual treatment costs £107 000/person. Nine individuals had cessation trials resulting in decline within 2 years prior and were not re‐challenged, leaving 36 eligible individuals. 12 of 36 (33.3%) consented to cessation trial and eight of those (66.7%) remained stable off treatment for ≥ 12 months. The successful cessation trials resulted in a cost saving of £855 000/year, with a potential further saving of £1.7 million/year if all the eligible individuals had consented. All patients who deteriorated were rescued to previous baseline on retreatment.
Interpretation
Individuals with CIDP should be counselled about the natural history of the disease and future scheduled, targeted cessation trials. A dedicated clinical infrastructure is vital to safely perform cessation trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, UCLH, London, UK.
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
ORCID-Profile: Shiwen Koay, Michael P Lunn
Förderung
- UCLH Biomedical Research Centre
Zitieren
APA
Koay, S., Chen, Y. C., Ransley, G., Compton, L., Lunn, M. P., & Carr, A. S. (2025). Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70007
Vancouver
Koay S, Chen YC, Ransley G, Compton L, Lunn MP, Carr AS. Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.70007
BibTeX
@article{Koay2025,
author = {Koay, Shiwen and Chen, Yi-Chun and Ransley, George and Compton, Laura and Lunn, Michael P and Carr, Aisling S},
title = {Safety and Cost Analysis of Immunoglobulin Cessation Trials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy},
journal = {Journal of the Peripheral Nervous System},
year = {2025},
doi = {10.1111/jns.70007}
}
EUVIMED